Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.39 | N/A | +34.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.39 | N/A | +34.86% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding market conditions. They reiterated their commitment to long-term growth strategies.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current pressures.
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.42% following the earnings report, likely due to the lack of revenue data and overall market concerns. Investors may be cautious as management did not provide guidance for future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHOTRONICS INC
Feb 20, 2023